NASDAQ$DERM

Journey Medical Corp · Q1 2025 earnings

Q1 2025 earnings · · After market close · Investor relations

Briefing

Journey Medical reported Q1 2025 revenue of $13.1M, a net loss of $4.1M.

For Q1 2025, Journey Medical reported Revenue was $13.1M, net loss was $4.1M. Management discusses operating trends, liquidity, and outlook in the quarterly filing.

  • Revenue $13.1M for Q1 2025.
  • Net loss $4.1M.
  • MD&A highlights operating priorities, liquidity, and sector-specific risks.

Headline financials

Total Revenue

$13M

Previous: $13M+0.1%
EPS (adj)

-$0.18

Previous: -$0.53+66.0%
Gross Margin

64.0%

Previous: 54.0%+18.5%
Net Income

-$4.07M

Previous: -$10.4M+61.0%
Operating Income

-$3.32M

Previous: -$10.1M+67.1%
Gross Profit

$8.35M

Previous: $6.21M+34.4%

Revenue & EPS history

Journey Medical · Revenue · Quarterly

$13M

Q1 2025+0.1%vs Q1 2024
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

Management emphasizes path to profitability, liquidity, and cost discipline.

Tailwinds

  • Operating initiatives and partnership milestones.
  • Cash runway and restructuring where applicable.

Headwinds

  • Operating losses and financing needs.
  • Macro and competitive uncertainty.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-2.9%

Avg return

Earnings day

-0.7%

Avg return

5 days after

+5.1%

Avg return

30 days after

39%

9 / 23 earnings

Positive

+22.0%

Q1 2025

Best reaction

-26.8%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-26.8%-1.1%—
Q1 2026+3.0%+24.4%+26.5%
Q3 2025-15.3%-12.4%-15.5%
Q2 2025-15.1%-18.0%-16.7%
Q1 2025+22.0%+15.2%+13.6%
Q4 2024-3.6%-2.8%+21.7%
Q3 2024-8.2%-7.5%-9.3%
Q2 2024-3.2%-11.0%-3.8%
Q1 2024+2.8%-1.7%+69.2%
Q4 2023-14.1%-3.9%-9.4%
Q3 2023+15.7%+14.8%+105.5%
Q2 2023+14.0%+4.7%+21.5%
Q1 2023-10.1%-23.2%+44.9%
Q4 2022+3.1%+13.1%+26.3%
Q3 2022-8.7%-9.2%-27.2%
Q2 2021-4.3%-7.0%-30.1%
Q2 2022-4.3%-7.0%-30.1%
Q1 2022-12.3%+5.1%+0.8%
Q1 2021-12.3%+5.1%+0.8%
Q4 2021+5.4%+6.1%-1.8%
Q3 2020+3.4%-0.1%-24.3%
Q4 2020+3.4%-0.1%-24.3%
Q3 2021+0.0%+0.0%-25.5%
Q2 2020———
Q1 2020———
Q3 2019———
Q2 2019———
Q1 2019———
Q4 2018———
Q3 2018———
Q2 2018———
Q1 2018———
Q4 2017———
Q3 2017———
Q2 2017———
Q1 2017———
Q4 2016———
Q3 2016———
Q2 2016———
Q1 2016———
Q4 2015———
Q3 2015———
Q2 2015———
Q1 2015———
Q4 2014———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro